publication date: Jul. 10, 2015

ORIEN Partners with Three Cancer Research Centers

 

The Oncology Research Information Exchange Network July 9 announced the addition of three cancer institutions to its precision cancer research partnership, bring the total number of partners to nine.

The new members are the Rutgers Cancer Institute of New Jersey, the University of Southern California Norris Comprehensive Cancer Center, and Morehouse School of Medicine.

“Becoming part of ORIEN adds great opportunities for Rutgers Cancer Institute of New Jersey, enabling discovery based on large-scale, diverse population data as well as patient-specific clinical decision support across a broad, national clinical trial portfolio,” said Robert DiPaola, director of the Rutgers Cancer Institute.

Launched In May 2014, ORIEN is a big data research partnership between U.S. cancer centers led by Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

ORIEN is designed to enhance precision cancer medicine efforts already in place at member organizations by enabling unprecedented research opportunities driving greater collaboration. All ORIEN members use a single protocol, Total Cancer Care (The Cancer Letter, March 13).

“It was a natural fit for USC Norris Comprehensive Cancer Center to join ORIEN, as personalized patient care has been a key component of our strategic plan,” said Stephen Gruber, Norris’ director. “We are proud to partner with ORIEN founders and members to collaborate to change the treatment model for oncology.”

To date, more than 124,000 patients have agreed to … Continue reading 41-27 ORIEN Partners with Three Cancer Research Centers

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.